Bausch Health Companies (BHC) Projected to Post Quarterly Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is expected to be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Bausch Health Companies to post earnings of $1.12 per share for the quarter. Bausch Health Companies has set its FY 2025 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 650.39%. The company had revenue of $2.56 billion during the quarter, compared to analysts’ expectations of $2.51 billion. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Bausch Health Companies Price Performance

BHC opened at $7.18 on Tuesday. The firm has a market capitalization of $2.64 billion, a PE ratio of -59.79, a price-to-earnings-growth ratio of 0.38 and a beta of 0.68. The business’s 50-day moving average is $7.34 and its two-hundred day moving average is $7.52. Bausch Health Companies has a 1 year low of $3.96 and a 1 year high of $11.46.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BHC shares. Royal Bank of Canada lowered their price target on Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price target (down previously from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.